• Alias: MEDI4736
    • A human Ig G1 kappa monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80 (B7.1); PD-L1 blockade leads to increased T-cell activation, allowing T cells to kill tumor cells
    • FDA approved on August 28, 2017 for locally advanced or metastatic urothelial carcinoma or unresectable NSCLC
    • Recommended dose: 10 mg/kg IV every 2 weeks
    • Half-life: â™17 days
    • Common side effects: Fatigue, skin rash, muscle pain, peripheral edema, abdominal pain, lymphocytopenia, constipation
    Other topics in Targeted and Immunotherapy Agents